Aptinyx developing drug for PTSD treatment
EVANSTON -- Aptinyx Inc. Thursday presented positive data from its Phase 2 study of a drug to treat patients with post-traumatic stress disorder. The study was presented at the Society of Biological Psychiatry annual meeting, being held virtually through Saturday.
The Phase 2 study evaluated the drug in 153 patients with PTSD. The study consisted of two, four-week treatment stages comparing once-daily oral dosing of 10 or 50 milligrams, compared to a placebo.
"The lack of effective pharmacotherapies in PTSD make the results from this study important," said Dr. Murray Stein, Distinguished Professor of Psychiatry and Public Health at the University of California San Diego and a consultant to Aptinyx. "While there have been numerous attempts to bring new therapies forward in PTSD, it has proven to be a very challenging indication."
Aptinyx, a clinical-stage biopharmaceutical company developing therapies for the treatment of brain and nervous system disorders, plans to incorporate this data into its next, larger study of the drug in PTSD patients, the company said.